September 20 – 22, 2017 | San Diego, CA
Sheraton San Diego Marina


NEW ADC & IO Combo Day


Wednesday September 20


Chair’s Opening Remarks

        Jay Harper, Senior Scientist, MedImmune

ADC & IO Combinations 2017: Where Have we Come From & What will the Future Hold?

  •  Explore clinical landscape of combining ADCs with immuno-oncology combinations
  • Review current approaches of combining ADCs with immune checkpoint inhibitors
  • Improve understanding of the scientific rationale for combination therapy

      Jay Harper, Senior Scientist, MedImmune

Improving Understanding of Scientific Rationale for Effective Combination Therapies


Combination Approaches with Immune Checkpoint Inhibitors & Immunomodulatory Agents to Enhance Folate Receptor-α/β Targeted Chemotherapy: Learning from Animal Models

  • While immune cell infiltration varies greatly among different cancer types, folate receptortargeted small-molecule drug conjugates can modulate tumor microenvironment according to their unique mechanism of action
  • EC1456, a folate-targeted microtubule depolymerizing agent, work synergistically with anti-PD-1 antibody against a lung carcinoma model and with a standard-of-care agent against a renal cell carcinoma model
  • EC2629, a folate-targeted DNA alkylating agent with anti-FRβ+ TAM activity, can effectively treat both FRα- and FRα+ TNBC models and its effect against ovarian cancer can be further enhanced by concurrent anti-CTLA-4 treatment

           June Lu, Director, Translational Research, Endocyte


Morning Break & Networking


ADCs: Preferred Partners for Checkpoint Inhibitors

  • Overview of immunogenic cell death and the hallmark features associated with that process
  • Detail Seattle Genetics in vitro data characterizing auristatin mediated immunogenic cell death and subsequent immune activation
  • Highlight the immune activation seen in vivo with auristatin ADCs
  • Provide evidence that auristatin ADCs pair with checkpoint inhibitors to drive a robust anti-tumor response preclinically and highlight data from the 2016 ASH presentation on the BV/Nivo combination study

    Shyra Gardai, Associate Director, Seattle Genetics

Think Tank Roundtable Sessions

More practical and highly interactive breakout roundtables where attendees can crowdsource solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the
findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion for information dissemination.

Lunch & Networking

 Clinical Learnings of ADC & Immune Checkpoint Modulators Combinations


Clinical Case Study: Clinical Learning from Mirvetuximab Soravtansine (IMGN853)  and Pembrolizumab Combination Therapy

  • Improve understanding of the synergy of combining ADC with immune checkpoint inhibitors
  • Explore the rationale for combining mirvetuximab soravtansine with pembrolizumab
  • Review most up to date clinical data

       Anna Berkenblit, Chief Medical Officer, ImmunoGen


Afternoon Networking

The Future: Evaluating Future Development of ADC & IO Combinations


Panel Discussion: Challenges & Opportunities with ADC & IO Combos

  • Lessons learned from progress in the field so far
  • Evaluating opportunities over the next 12 months
  • How do different stakeholders need to contribute?

       Louie Naumovski, Senior Medical Director, AbbVie


Chair’s Closing Remarks

         Jay Harper, Senior Scientist, MedImmune


Poster Session & Drinks Reception